NILO-PD

A study of nilotinib in people with Parkinson's disease

Have you had Parkinson's disease for over 5 years?
AND
Have you been taking medication(s) to treat your PD symptoms?

If you answered yes to both questions, you may be a potential candidate for the Nilotinib in Parkinson's Disease Study (NILO-PD). Nilotinib is currently approved by the U.S. Food and Drug Administration (FDA) to treat a cancer of the white blood cells. This study will evaluate the safety and tolerability of nilotinib in Parkinson's disease. It will also explore nilotinib' s potential to treat symptoms, or to slow or stop disease progression in future studies.

You may qualify for this study if you:

- You are between **40** and **79** years of age
- You have had PD for at least 5 years
- You have been on a stable regimen of PD medications for at least 30 days prior to the screening visit
- You are willing to undergo 2-3 lumbar punctures

What is involved if I participate?

- Your participation will last approximately **8** to **9** months and will include 13 in person clinic visits
- Participants will be randomly assigned to receive daily oral doses of nilotinib or placebo – an inactive pill used in research studies to determine if the active study drug is effective.
- Several blood samples will be collected throughout the study, along with required Lumbar Punctures at certain visits.

If you are interested in participating or want to learn more, visit
www.nilopd.org or **foxtrialfinder.michaeljfox.org**
Or contact

Tina Ward
Phone: 1-877-483-1834
Email: nilo_study@chet.rochester.edu

PSG PARKINSON STUDY GROUP

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

This study is conducted through the Parkinson Study Group and funded by The Michael J. Fox Foundation for Parkinson's Research.